New financial prediction markets platform marks its introduction with a free November 3 event in Boston and live online, exploring what election night could mean for your portfolio

NEW YORK, Oct. 28, 2026 /PRNewswire/ -- SignalMarkets, a Prediction Markets platform affiliated with Crypto.com, today introduced its financial prediction markets platform and announced Signal Summit 2026: Watch Politics Move Markets in Real Time, a free, interactive election-night event taking place Tuesday, November 3, in Boston and live online.

Focused on economic, financial, business and political events, SignalMarkets brings an investment-oriented perspective to prediction markets. Signal Summit will introduce that perspective through live market commentary, interactive discussions and practical examples examining what changing political expectations could mean for investment decisions and portfolio risk.

Reserve your free place in Boston or join the livestream at signalmarkets.com. In-person seating is limited, and advance registration is required.

"Election night provides a particularly compelling setting to introduce SignalMarkets," said Joel Shulman, Founder of SignalMarkets. "As new information emerges, expectations can change rapidly. Signal Summit will give participants an opportunity to observe these developments, understand how markets respond and see why connections across markets matter."

What Could Election Night Mean for Your Portfolio?

Signal Summit will give investors, traders, financial advisers, portfolio managers and anyone interested in understanding prediction markets a framework for interpreting political developments through a financial lens.

Participants will explore:

- How politics can move markets: Examine how changing election expectations may influence the outlook for economic policy, inflation and interest rates.

- How developments across markets connect: Follow live commentary and practical examples examining the potential financial implications of new information.

- How prediction markets fit into the financial landscape: Understand how event-based financial trading compares with traditional investing and sports betting.

- An introduction to Signal Chains: Get a first look at SignalMarkets' perspective on interconnected markets.

The program is designed for participants at all experience levels. No prediction markets experience is required.

Reserve Your Free Place

Event: Signal Summit 2026

Theme: Watch Politics Move Markets in Real Time

Date: Tuesday, November 3, 2026

Start time: 6 p.m. ET

Location: Boston, Massachusetts, and live online

Admission: Free; advance registration required

In-person seating: Limited availability

Register at signalmarkets.com for event details and to reserve your place.

Online participants will receive livestream access information following registration.

About SignalMarkets

SignalMarkets is a financial prediction markets platform focused on economic, financial, business and political events. Founded by experienced investment professionals and academics, the company brings an investment-oriented perspective to event-based trading, market analysis and portfolio risk management. Through its emphasis on interconnected markets and Signal Chains, SignalMarkets seeks to help participants better understand how changing probabilities may influence financial decisions.

Trade the Signal. Not the Noise.

Website: signalmarkets.com

Participation in Signal Summit 2026 is educational and does not require trading. Event contracts involve financial risk, including the potential loss of the amount committed. Trading availability is subject to applicable regulatory and operational requirements.

SOURCE SignalMarkets

Share this article

New MCP connects Stockpress content libraries with AI tools, allowing teams to find, understand, and organize their assets simply by asking.

BOSTON, Oct. 28, 2026 /PRNewswire/ -- Stockpress, the Digital Asset Management (DAM) platform built for marketing, brand and creative teams, today announced the launch of its Model Context Protocol (MCP) server, opening up new ways for organizations to find, organize and put their existing content to work through the AI tools and LLMs, such as ChatGPT and Claude, they choose to use.

Organizations have spent years creating valuable images, videos, presentations, documents, and brand assets. But even the best content isn't much use if people can't find it, understand what's available, or put it to work.

And as AI becomes part of everyday work, there's a new opportunity: what if your AI tools could work with all that content, too? That's exactly what Stockpress MCP makes possible.

Stockpress MCP is available now. See how it works here.

Using Model Context Protocol, an open standard for connecting AI applications with external systems, Stockpress allows compatible AI tools to access and interact with the content organizations already manage in their workspace.

No new platform to learn. No moving files into another system. Just a new way to work with the content you've already got. Or as Stockpress CRO Ian Parkes frames it: "Don't just find your content. Put it to work."

With Stockpress MCP, teams can use everyday language to:

- Find the right assets: Search images, videos, documents and brand files using descriptions, tags, metadata and filters, without digging through folders.

- Get more from existing content: Ask AI to review images, recommend assets for campaigns, compare logo versions or identify content worth reusing.

- Organize without the legwork: Create Collections, gather relevant files and build Smart Collections that automatically update as matching content is added.

- Understand their content libraries: Identify untagged files, review metadata, uncover organizational gaps and better understand the content they already own.

- Turn content into something useful: Use connected AI tools to help create asset inventories, campaign recommendations and reports from content stored in Stockpress.

For marketing, brand and creative teams, that means less time hunting for files and more time putting them to good use.

"AI is only as useful as what it can see," said Jessica Storry, CEO and co-founder of Stockpress. "Our customers are working in AI tools every day, but their best content has been a few steps (and downloads!) away. Stockpress MCP closes that gap and brings their brand library into the tools where the work is already happening."

Your content stays. The possibilities grow.

The launch builds on the existing AI capabilities of Stockpress, including automatic tagging, facial recognition, text extraction, and video transcription, which help teams find and understand their content.

MCP takes that a step further, connecting Stockpress to the growing ecosystem of compatible AI applications while respecting existing workspace permissions.

Rather than building another AI workspace, Stockpress is making the tools organizations already use more capable by giving them access to the content they need. As Ian Parkes adds: "It's a natural evolution of DAM: from a place to store and manage content into a connected foundation for how people, platforms and AI work with it."

Your content stays in Stockpress. Where you put it to work is up to you.

Ready to try it? Learn how to connect a Stockpress workspace to LLMs like ChatGPT and Claude in our Help Center.

About Stockpress

Stockpress is an AI-powered Digital Asset Management (DAM) platform that helps marketing, creative, brand, and content teams organize, find, manage, and share digital assets without the complexity or cost of traditional enterprise DAM software.

With powerful AI features, Collections, version control, secure sharing, and integrations, Stockpress makes content accessible and useful across organizations. Transparent pricing, self-serve setup, and unlimited users on every plan make professional DAM simple to adopt and affordable to scale.

Company contact:

Ian Parkes - [email protected]

SOURCE Stockpress

Share this article

Boeing: Global Freighter Fleet to Exceed 4,000 Airplanes as Air Cargo Traffic Doubles by 2045

- Supply-chain diversification, e-commerce and AI-driven technology demand are driving growth and reshaping air cargo flows

- Nearly 3,000 new and converted freighters will be required over the next 20 years

MIAMI, Oct. 28, 2026 /PRNewswire/ -- Boeing [NYSE: BA] projects in its 2026 World Air Cargo Forecast that air cargo traffic will double over the next 20 years, driving the freighter fleet to exceed 4,000 airplanes by 2045. Growth will be fueled by time-sensitive shipments for advanced manufacturing and AI hardware, diversifying supply chains and rising e-commerce volumes as carriers adapt route networks to shifting trade lanes and manage geopolitical disruptions.

Boeing released its biannual forecast today at The International Air Cargo Association's Air Cargo Forum in Miami. The 20-year forecast examines major air trade markets, industry trends and the future development of the global freighter fleet.

Market snapshot

- Record traffic: Global air cargo traffic reached a new annual record in 2025, growing nearly 5% year over year from 2024, despite trade volatility and geopolitical disruptions.

- Network resilience: Air cargo networks are adapting to changing trade flows, rerouting challenges and shifting production locations while continuing to provide speed, reliability and security.

- Key demand drivers: E-commerce, direct-to-consumer business model and demand for high-tech goods are fueling air cargo growth. According to IATA, more than 70% of AI-related goods were transported by air in 2025.

World Air Cargo Forecast highlights and insights

- Fundamentals: Structural growth drivers and proven resilience are expected to support air cargo traffic growth of 3.5% annually over the next two decades, outpacing long-term economic and trade growth. Trade flows touching Asia will lead growth and represent approximately 60% of the global market.

- Freighter fleet growth: The worldwide fleet is expected to grow 67% by 2045 from 2,395 airplanes in 2025 to 4,010 airplanes. Dedicated freighters are expected to carry more than half of global air cargo traffic in the long term.

- Growth and replacement: Operators will need 2,930 new and converted freighters over the next 20 years to support traffic growth and replace retiring airplanes. About 55% of deliveries will add capacity; approximately 45% will replace older, less efficient freighters. Two-thirds of deliveries will be converted passenger airplanes and the remainder will be new-production freighters.

- Market mix: Nearly one-third of all air cargo revenues are earned by airlines with passenger belly cargo capacity as well as dedicated main deck freighters to serve a broad network and diverse markets. Growing demand for express services will lift integrators' (time-definite and express operators) share of global air cargo traffic to nearly 25% in 2045.

"Air cargo's adaptability and speed are strategic advantages enabling reliable transport, dynamic rerouting and critical support for evolving supply chains," said Darren Hulst, Boeing vice president of Commercial Marketing. "As global trade patterns change and demand for time-sensitive, high-value goods grows, dedicated freighters will remain essential to global commerce."

About the global air cargo market

- Goods transported by air tend to be perishable, high-value and time-sensitive. Though they represent less than 1% of global trade by volume, they account for roughly one-third of global trade value.

- Approximately 55% of global air cargo traffic, measured in cargo tonne-kilometers, has historically been transported by main-deck freighters, underscoring the importance of dedicated aircraft to global trade.

- In 2025, airlines with freighter operations, including cargo-only and passenger airlines, accounted for approximately 90% of air cargo industry revenue of approximately $170 billion.

The full 2026 World Air Cargo Forecast is available at boeing.com/wacf.

A leading global aerospace company and top U.S. exporter, Boeing develops, manufactures and services commercial airplanes, defense products and space systems for customers in more than 150 countries. Our U.S. and global workforce and supplier base drive innovation, economic opportunity, sustainability and community impact. Boeing is committed to fostering a culture based on our core values of safety, quality and integrity.

Caution Concerning Forward-Looking Statements

This document contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "should," "expects," "intends," "projects," "plans," "believes," "estimates," "targets," "anticipates," and other similar words or expressions, or the negative thereof, generally can be used to help identify these forward-looking statements. Examples of forward-looking statements include statements relating to future demand for commercial airplanes and aviation personnel, as well as any other statement that does not directly relate to any historical or current fact. Forward-looking statements are based on expectations and assumptions that we believe to be reasonable when made, but that may not prove to be accurate. These statements are not guarantees and are subject to risks, uncertainties, and changes in circumstances that are difficult to predict. Many factors, including economic conditions in the United States and globally, general industry conditions as they may impact us or our customers, and other important factors disclosed previously and from time to time in our filings with the U.S. Securities and Exchange Commission, could cause actual results to differ materially and adversely from these forward-looking statements. Any forward-looking statement speaks only as of the date on which it is made, and we assume no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Contact

Boeing Media Relations

[email protected]

SOURCE Boeing

Share this article

$60 million investment expands Gradian's capacity across air handling, liquid cooling, and chillers for mission-critical thermal management

DAYTON, Minn., Oct. 28, 2026 /PRNewswire/ -- Gradian Thermal Solutions, a leading U.S. designer and manufacturer of advanced thermal management solutions for mission-critical environments, today announced the grand opening of its new 500,000-square-foot manufacturing facility in Dayton, Minnesota, an investment of approximately $60 million. Production began at the facility in June, and Gradian continues to ramp up capacity.

Together with the company's 180,000-square-foot Maple Grove, Minnesota facility and the 100,000-square-foot facility in Guadalajara, Mexico, the Dayton expansion brings Gradian's manufacturing footprint to approximately 780,000 square feet and establishes the company as a significant player in thermal management for mission-critical applications.

Gradian expects the investment to significantly expand its manufacturing capacity, supporting strong and growing demand from data center, industrial, and commercial customers. The company also expects to grow its workforce from approximately 150 employees to around 1,000 companywide.

This site expands Gradian's capacity to build its established portfolio of thermal management solutions, which spans liquid cooling, chillers, air handling, commissioning products, and prefabricated solutions. The facility includes assembly lines, fabrication equipment, and an end-of-line testing lab for our chiller product line, all supporting Gradian's data center, industrial, and commercial customers.

"The Dayton expansion is a deliberate investment in our ability to meet the growing demands of mission-critical thermal management applications for our ever-growing customer base," said Jason Ulett, Chief Operating Officer of Gradian. "At the core of this expansion is a vertically integrated operating model, enabling dedicated assembly and testing capabilities specifically designed to ensure quality, performance, and scalability."

Dayton offered the space and the location Gradian needed. The facility is large enough to support the company's growth and sits close to Gradian's Maple Grove headquarters, allowing the core management team to work easily across both sites. Gradian has also had strong experiences with the area's workforce and is excited to continue growing in Minnesota.

Gradian is hiring for many roles across the Dayton facility, including engineering, project management, and accounting, as well as production, fabrication, and assembly. Candidates can view current openings and apply at linkedin.com/company/gradian-solutions/jobs.

As an engineering-led, full-line thermal solutions partner, Gradian is building the capacity, the portfolio, and the operating model to meet the evolving thermal management needs of mission-critical customers, and it plans to continue expanding across North America.

About Gradian Thermal Solutions

Gradian is a leading U.S. designer and manufacturer of advanced thermal management solutions for mission-critical environments. The Company specializes in rapid customer-focused response and deployment, with engineered-to-order products designed to meet complex customer requirements. Gradian offers a comprehensive portfolio of liquid cooling, air handling, chiller, and integrated modular HVAC solutions for mission-critical environments. For more news and information about Gradian, please visit gradiansolutions.com.

Media Contact

Jessica Smaagaard

Chief Human Resource Officer

[email protected]

SOURCE Gradian Thermal Solutions

Share this article

Program supports the next generation of leaders in their journeys toward careers in agriculture and STEM

RALEIGH, N.C., Oct. 28, 2026 /PRNewswire/ -- Syngenta awarded five college students $2,000 each through the Durastak Traits of Tomorrow Scholarship, a new program designed to support the success of the young adults building the future of agriculture.

The winners of the 2026 Durastak Traits of Tomorrow Scholarship are:

- Sophia Barnum, Michigan State University, Crop and Soil Sciences

- Braydon Binger, University of NebraskaâLincoln, Agronomy

- Kaarina Dunn, University of WisconsinâMadison, Environmental Sciences and Agroecology

- Ethan Fisher, Kansas State University, Biological Systems Engineering

- Calvin Myers, Purdue University, Agribusiness Management

Recipients were selected by a panel of judges based on the merits of their applications and their demonstration of determination, resourcefulness and a forward-thinking mindset. The scholarship was open to seniors in high school or full-time students across the Midwest pursuing a degree in a science, technology, engineering, mathematics or agriculture-related field of study.

"We're proud to support the next generation of agricultural leaders with this scholarship opportunity," said Steve Sterchi, Head of Product & Commercial Strategy at Syngenta. "These five recipients are proof that the future of agriculture is in great hands, and we're excited to see the impact young people like them will make on the industry."

Scholarship recipient Ethan Fisher is studying agricultural engineering with the plan to start his own operation after graduation and help move the industry forward through the challenges it's facing today.

"Agriculture is an ever-changing world, it's never going to stop advancing, I don't think. It takes a lot to figure out how to build an operation from nothing nowadays and that's a task that I personally want to tackle," said Fisher. "Thank you for helping me cover my educational expenses, thank you for realizing that I want to be part of the solution here."

Another recipient, Kaarina Dunn, plans to pursue a career in agricultural policymaking at the state or national level to help farmers get the governmental assistance they need and teach young people about the importance of the agriculture industry.

"This scholarship shows youth that agriculture isn't something that just happens on a family farm, it happens in universities, it happens in classrooms all across the world," said Dunn. "I think hands-on agriculture work is obviously the way of the future. It's how youth learn about what they're eating every single day, where it comes from and how our local communities are impacted by the choices that we make in grocery stores."

To learn more about these recipients and see how Syngenta is committed to investing in the future of the agriculture industry, visit https://www.syngenta-us.com/seeds/corn-traits/durastak-scholarship.

About Syngenta

Syngenta is a leading science-based agricultural technology (AgTech) company, creating Breakthroughs for farmers, in every field⢠to help meet the demands of modern agriculture. Using cutting-edge innovation and guided by its Sustainability Goal of higher yields with lower impact, Syngenta helps farmers to grow resilient, healthy crops that can feed a growing global population, while protecting and enhancing the planet. Syngenta is part of Syngenta Group, headquartered in Switzerland. To find out more about how Syngenta creates breakthroughs for farmers around the world, read our stories and follow us on social media.

Data protection is important to us. For more information about how we collect, use, disclose, transfer and store your information, you can review our Privacy Policy.

Cautionary Statement Regarding Forward-Looking Statements

This document may contain forward-looking statements, which can be identified by terminology such as 'expect', 'would', 'will', 'potential', 'plans', 'prospects', 'estimated', 'aiming', 'on track' and similar expressions. Such statements may be subject to risks and uncertainties that could cause the actual results to differ materially from these statements. For Syngenta, such risks and uncertainties include risks relating to legal proceedings, regulatory approvals, new product development, increasing competition, customer credit risk, general economic and market conditions, compliance and remediation, intellectual property rights, implementation of organizational changes, impairment of intangible assets, consumer perceptions of genetically modified crops and organisms or crop protection chemicals, climatic variations, fluctuations in exchange rates and/or commodity prices, single source supply arrangements, political uncertainty, natural disasters, and breaches of data security or other disruptions of information technology. Syngenta assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

© 2026 Syngenta. Important: Always read and follow label and bag tag instructions; only those labeled as tolerant to glufosinate may be sprayed with glufosinate ammonium-based herbicides.

LibertyLink®, Liberty® and the Water Droplet logo are registered trademarks of BASF. HERCULEX® and the HERCULEX Shield are trademarks of Corteva Agriscience LLC. HERCULEX Insect Protection technology by Corteva Agriscience LLC.

YieldGard VT Pro⢠is a trademark used under license from the Bayer Group.

More information about Syngenta seed products is available at http://www.biotradestatus.com/. Trademarks are the property of their respective owners.

SOURCE Syngenta Seeds, LLC

Share this article

Innoviz Sees Strong Counter-UAS Demand at AUSA 2026, Reinforcing the Fit of Innoviz Perciz for U.S. Defense and Homeland Security Markets

Meetings with senior leaders of major defense companies and dozens of prospective customers highlight a growing need for precise 3D localization to counter low-cost drone threats, including FPV and fiber-optic drones.

TEL AVIV, Israel, Oct. 28, 2026 /PRNewswire/ -- Innoviz Technologies Ltd. (NASDAQ: INVZ) ("Innoviz" or the "Company"), a leading supplier of high-performance, automotive-grade LiDAR sensor platforms for autonomous driving, defense and homeland security, industrial, and smart infrastructure applications, today shared highlights from its attendance at the Association of the United States Army (AUSA) Annual Meeting and Exposition, held October 12-14, 2026, at the Walter E. Washington Convention Center in Washington, D.C. Over three days, Innoviz executives met with CTOs and senior leaders of leading defense companies, system integrators, and dozens of prospective customers, with counter-unmanned aircraft systems (C-UAS) at the center of the conversation.

AUSA is North America's largest land power exposition and professional development forum. Innoviz's participation came three months after the Company launched Perciz, its dedicated defense and homeland security brand, and followed its first multimillion-dollar orders from a defense customer, announced in July 2026, to power counter-drone systems and perimeter intrusion detection applications.

Counter-UAS at the Center of the Conversation

Throughout the exposition, the threat posed by small, inexpensive drones, including first-person-view (FPV) drones, was one of the most widely discussed topics among military leaders, defense primes, and technology providers. Discussions repeatedly returned to a shared operational challenge: existing sensors can alert operators that a drone is present but often cannot fix its position precisely enough to engage it quickly and cost-effectively. Fiber-optic controlled drones, which emit no radio signal, further limit the effectiveness of RF-based detection and jamming.

Across its meetings, Innoviz heard consistent demand for two capabilities: high-resolution 3D sensing that delivers the precise, real-time position of a drone, and perception software that supports drone tracking and positive identification (PID). Innoviz believes its automotive-grade LiDAR, offered for defense and homeland security under the Perciz brand, is well positioned to address both needs as part of a layered C-UAS architecture.

Why Perciz Fits the Counter-UAS Mission

Perciz brings Innoviz's production-ready, automotive-grade LiDAR platform, selected by BMW, Volkswagen, Mobileye and Daimler Truck, to defense and homeland security applications. In the context of the needs raised at AUSA, Perciz offers:

Precise 3D localization: Centimeter-level 3D positioning with the potential to replace a circle of uncertainty with a precise coordinate that interceptors and effectors can act on.

Resilience to signal-based evasion: As an active optical sensor that responds to the physical world rather than to emitted signals, LiDAR is well-positioned not to depend on whether a drone is RF-controlled, autonomous, or fiber-optic guided.

Performance in cluttered and harsh environments: High-resolution point cloud data helps separate drones from background clutter such as fences, vegetation, and structures, with blockage resilience against rain, mud, and debris.

Cost-effective response: Precise localization supports lower-cost interception methods, helping close the gap between the cost of a drone and the cost of the systems traditionally used to defeat it.

"AUSA was one of the busiest and most energizing conferences I have attended in many years," said Omer Keilaf, Founder and CEO of Innoviz Technologies. "What we heard again and again is that defense organizations can detect drones, but they need to know exactly where they are. Innoviz Perciz is well-positioned to deliver a coordinate accurate enough to guide an effective response - not just flag a general area, and it is based on the same automotive-grade precision trusted by leading carmakers."

"The response we received at AUSA exceeded our expectations," said Jeremie Kletzkine, Vice President of Business Development at Innoviz. "We arrived with a full calendar of meetings scheduled in advance, and the exposition quickly generated many more introductions, including with technology leaders at some of the most important players in the counter-UAS space. The interest from U.S. integrators and prime contractors supports a real need for LiDAR combined with perception software for drone tracking and identification. Our focus now is on turning these conversations into evaluations and long-term collaborations with U.S. customers and partners."

Building Momentum in the U.S. Defense Market

Innoviz is now following up on a significant number of new opportunities identified at the exposition, the majority of them related to C-UAS applications. Innoviz's engagement at AUSA was supported by Maj. Gen. (Ret.) Yoav Har-Even, former President and CEO of Rafael Advanced Defense Systems and Chairman of the Innoviz Board of Directors, who helped introduce the Company to senior leaders across the defense industry.

The exposition builds on the momentum of Perciz since its launch in July 2026, including the Company's first multimillion-dollar defense orders and collaborations with several defense and C-UAS providers. Innoviz plans to continue expanding Perciz's presence in the U.S. defense and homeland security market, including at upcoming industry events such as C-UAS Technology USA taking place on November 30-December 2 in Washington, D.C.

About Innoviz

Innoviz is a leading provider of LiDAR technology, serving as a Tier-1 supplier to the world's leading automotive manufacturers while extending its existing sensing solutions into defense, homeland security, industrial, and smart infrastructure markets.

Innoviz's LiDAR sensors and complementary software suite are designed to deliver exceptional range, resolution, and reliability, providing accurate 3D sensing even in harsh weather conditions. Built to meet the automotive industry's strict standards for performance and safety, Innoviz's sensors are increasingly supplied for applications that demand precise, real-time spatial awareness and continuous object localization.

Operating across the U.S., Europe, and Asia, Innoviz designs solutions for automotive OEMs, system integrators, municipalities, commercial enterprises, government organizations, and other customers worldwide. Under the Perciz brand, Innoviz offers its existing automotive-grade LiDAR sensors for defense, counter-UAS, perimeter intrusion detection, and homeland security applications.

For more information, visit innoviz.tech.

About Innoviz Perciz

Perciz is Innoviz's dedicated defense and homeland security brand, focused on using Innoviz's existing LiDAR solutions for defense, homeland security, and critical infrastructure applications. By using Innoviz's rich data, we believe operators will be able to perceive, understand, and act in the physical world with greater intelligence and precision. Perciz has the ability to support the next-generation defense and homeland security systems designed to address the increasing complexity of modern threats. For more information, visit innoviz.tech/perciz.

Join the discussion: Facebook, LinkedIn, YouTube, X

Media Contact

[email protected] 

Investor Contact

[email protected]

Forward Looking Statements

This announcement contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding the services and products offered by Innoviz, the anticipated technological capability of Innoviz's products, including performance under various environmental and operational conditions, the markets in which Innoviz operates, and the Company's ability to successfully enter and compete in the defense and homeland security markets, and the potential for synergies between the Company's automotive and defense market activities. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "design(ed)," "strategy," "future," "opportunity," "plan," "potential," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions.

Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties.

Many factors could cause actual future events to differ materially from the forward-looking statements in this announcement, including but not limited to, the ability to implement business plans, forecasts, and other expectations, the ability to achieve broader market adoption of Innoviz's products and solutions, the risks associated with the defense and homeland security market, including procurement cycles, budgetary constraints and regulatory and export control considerations, the early stage of the Company's defense and security business, and our expectations regarding the impact of geopolitical developments in the Middle East including the evolving conflict in Israel on our ongoing operations. The foregoing list is not exhaustive. You should carefully consider such risks and the other risks and uncertainties described in Innoviz's annual report on Form 20-F for the year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission ("SEC") on March 4, 2026, and in other documents filed by Innoviz from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements.

CellectGen Advances Periodontal Diagnostics in Collaboration with Kemp Proteins and DCNDx

FREDERICK, Md., Oct. 28, 2026 /PRNewswire/ -- CellectGen has received Small Business Innovation Research (SBIR) funding to develop a saliva-based, point-of-care diagnostic platform for periodontal disease, focused on early detection of active tissue destruction.

About 42% of U.S. adults over 30 have periodontal disease, a leading cause of adult tooth loss that contributes to an estimated $154 billion in direct and indirect costs. Yet clinicians still struggle to identify patients with active disease before irreversible damage appears. Current diagnostics mostly detect existing clinical disease or risk factors, and commercial saliva tests primarily measure bacterial or host biomarker signatures rather than tissue destruction itself.

CellectGen's platform measures different molecular forms of a highly specific enzyme associated with the breakdown of periodontal soft and hard tissue. Telling these forms apart has been difficult because antibodies with the necessary specificity were lacking. Working with Kemp Proteins, CellectGen has developed and validated hybridoma-derived monoclonal antibodies that distinguish among these forms. Kemp's antibody development and manufacturing capabilities provide the sensitivity, specificity, batch-to-batch consistency and traceability that regulated diagnostics require.

"Our platform will help clinicians answer three critical questions: What is the level of active tissue destruction? What is the patient's risk of future disease progression? And is the current therapy working?" said Robert Gellibolian, CEO of CellectGen. "The SBIR funding enables us to advance this approach, while our collaboration with Kemp provides critical antibody reagents for continued assay development with the team at DCNDx."

DCNDx turns the antibodies into a usable test. These proprietary antibodies are now being built into a rapid saliva test with DCNDx, a Carlsbad, CA-based developer specializing in lateral-flow assay technologies. DCNDx is responsible for the step between a validated reagent and a working product: designing and optimizing the lateral-flow format around CellectGen's antibodies, tuning the assay to deliver quantitative rather than simply yes/no results, and ensuring it performs reliably with real saliva samples. Its work targets results in under 15 minutes, in a format simple enough for both chairside and at-home use. DCNDx's experience in lateral-flow development also helps move the test toward a consistent, manufacturable product that can scale beyond the lab.

"Diagnostics are only as strong as the reagents behind them," said Mike Keefe, CEO of Kemp Proteins. "We're pleased to support CellectGen's work as they develop a platform aimed at detecting periodontal disease activity earlier and closer to the patient."

"It's been great working with CellectGen on this new periodontal test and collaborating with Kemp Proteins on reagent development. Together, we're bringing a fast, quantitative lateral-flow assay from the lab to chairside and at-home use," remarked Patrick Vaughan, COO at DCN Dx.

Together, the three companies span the development continuum: CellectGen's biomarker and platform technology, Kemp's reagent development and manufacturing, and DCNDx's lateral-flow expertise. The technology aims to give clinicians predictive, actionable insight into the biological drivers of ongoing, subclinical tissue destruction, supporting earlier identification, progression monitoring and evaluation of treatment response.

About CellectGen

CellectGen's mission is to improve periodontal screening and treatment outcomes by giving clinicians the right information, in the right place, at the right time. The company is developing a decentralized, saliva-based point-of-care platform that quantifies molecular markers of periodontal tissue destruction.

About Kemp Proteins

Kemp Proteins is a protein problem-solving company that helps researchers and developers overcome the challenges of difficult proteins and antibodies. Operating under an ISO 13485 Quality Management System, Kemp develops, produces and characterizes proteins for diagnostic, biopharmaceutical and research applications, combining scientific expertise and machine learning with practical, scalable solutions.

About DCNDx

DCNDx is a specialist developer of diagnostic tests built on lateral-flow technology, supporting clients from early assay development through clinical research, regulatory support and manufacturing. Its integrated engineering and science teams design the assay together with the cassette and sample-handling device, so the two are optimized as one system. The company also develops point-of-care readers and instrumentation, and offers training and consulting in rapid assay development.

SOURCE Kemp Proteins

Share this article

The newly created role puts physician and CRNA executives side by side at the top of Sound Anesthesia's clinical leadership

NASHVILLE, Tenn., Oct. 28, 2026 /PRNewswire/ -- Sound Physicians has appointed Emil Engels, MD, MBA, as Chief Physician Officer for Sound Anesthesia. Dr. Engels is a cardiac anesthesiologist and physician executive with more than 25 years of experience leading anesthesia practices and healthcare organizations. He joined the medical group in September to partner with Sound Anesthesia's physician leaders and support operational excellence and clinical quality initiatives across the specialty.

Sound Anesthesia created the Chief Physician Officer role to work alongside Noele Morse, DNP, CRNA, Chief Anesthetist Officer. Together, Dr. Engels and Morse bring complementary physician and CRNA perspectives to the specialty's leadership, with a similar collaborative approach reflected in the associate-level roles.

"Our physician anesthesiologists and CRNAs care for patients together every day, and our leadership should reflect that," said David Leachman, MD, Chief Executive Officer, Sound Anesthesia. "Dr. Engels has led anesthesia practices across multiple states and served as CEO of an orthopedic organization, so he knows what hospitals and surgeons need from an Anesthesia partner. With Emil and Noele working as a team, our clinicians and partners benefit from close collaboration between the physician and CRNA perspectives within the Anesthesia care team."

Most recently, Dr. Engels served as CEO of Aligned Orthopedic Partners. There, he grew the organization through strategic acquisitions and new ancillary services, oversaw ambulatory surgery centers, and championed value-based care initiatives with the organization's surgeons. Earlier, as Market President for Mednax, he oversaw 12 anesthesia practices across four states. He also chaired a 150-clinician anesthesia practice that covered two major tertiary care hospitals. He spent nearly 20 years as a cardiac anesthesiologist at Inova Health System and taught at the University of Virginia School of Medicine.

Dr. Engels has served on the American Society of Anesthesiologists Board of Directors and as president of the Virginia Society of Anesthesiologists. He earned his undergraduate degree from the University of Virginia and his medical degree from Yale School of Medicine. He completed his anesthesiology residency and cardiac anesthesia fellowship in the Harvard University system and holds a Master of Business Administration degree from the University of Tennessee.

"A surgical day runs well when physicians, CRNAs, surgeons, and OR staff work from the same plan," said Dr. Engels. "Sound has built that partnership into its leadership structure, and I'm glad to share the work with Noele. I want our clinicians to have the support they need to practice at the top of their licenses, and I want our hospital partners to see it in on-time starts and a consistently strong experience for their surgeons."

About Sound Physicians

As a physician-founded and led medical group, our priority is building lasting partnerships with hospitals and health systems to ensure every patient receives the care they need â and deserve. Shaped over two-plus decades by clinical excellence and well-honed business acumen, we're proud to have more than 4,000 clinicians serving across emergency and hospital medicine, critical care, and anesthesia. Through these specialties, we touch the lives of millions of patients each year in local communities across 45 states. We also support the health and well-being of tens of thousands of long-term care residents, some of the most vulnerable patients, through our accountable care organization. From addressing universal challenges to unique community needs, we help our partners and clinical teams thrive today and well into the future. For more information, visit SoundPhysicians.com

Media Contact

Supreme Communications for Sound Physicians

[email protected]

SOURCE Sound Physicians

Share this article

The Countdown Is On: BOTOX® Cosmetic (onabotulinumtoxinA) Day is Back Nov. 18

- The holiday celebrates personalized treatment with BOTOX® Cosmetic across four FDA-approved aesthetic indication areas, the one and only of its kind in the United States.1

- BOTOX® Cosmetic Day marks the biggest offer of the year for AllÄ Members.

IRVINE, Calif., Oct. 28, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the return of BOTOX® Cosmetic Day on Wednesday, Nov. 18, 2026. Now in its eighth year, BOTOX® Cosmetic Day invites new and existing patients to book a comprehensive consultation with a licensed aesthetic specialist to discuss their personalized treatment options. In addition to a BOGO (buy-one-get-one) free $50 gift card offer*, the brand's biggest offer of the year, AllÄ Members who refer a friend in November will receive $50 off any qualifying AllÄ product or treatment.â

BOTOX® Cosmetic is the only FDA-approved neurotoxin in the U.S. that temporarily improves the look of four aesthetic indication areas including moderate to severe frown lines, crow's feet, forehead lines and vertical bands connecting the neck and jaw (platysma bands) in adults.1 Full results were seen in 30 days for upper facial lines (frown lines, crow's feet and forehead lines).1,II The treatment also delivers the natural-looking results patients want, with a recent study finding that approximately 90% of patients treated with BOTOX® Cosmetic in their upper facial lines reported satisfaction with how natural their results looked at Day 30.3,â¡

"Allergan Aesthetics is committed to investing in the category BOTOX® Cosmetic helped create by fueling innovation that will shape its future§," said Glen Curran, senior vice president, U.S. Allergan Aesthetics. "BOTOX® Cosmetic Day gives aesthetic providers the opportunity to celebrate this continued momentum with the millions of patients who confidently choose BOTOX® Cosmetic for its subtle, natural-looking results.2"

Through AllÄ, the Allergan Aesthetics loyalty rewards program, Members can take advantage of two exclusive BOTOX® Cosmetic Day offers:

- BOGO free gift card: On Wednesday, Nov. 18, beginning at 9 a.m. PT, while supplies last, AllÄ members who purchase a $50 gift card will receive an additional $50 gift card at no cost. Cards may be used personally or given as gifts and are redeemable for future BOTOX® Cosmetic treatments with participating AllÄ providers.*

- Refer a Friend: AllÄ Members who refer a friend during the month of November will receive $50 off any qualifying AllÄ product or treatment, as will their friend.â

"Most of my patients tell me the same thing: they want to look like themselves, just with fewer lines. I choose BOTOX® Cosmetic as my go-to aesthetic neurotoxin to temporarily improve the look of moderate to severe upper facial lines and platysma bands while tailoring treatment to each patient," said board-certified dermatologist Dr. Anthony Rossi, FAAD, FACMS, and Allergan Medical Institute (AMI) trainer. "BOTOX® Cosmetic Day is a great opportunity for aesthetic providers to slow down and really talk with patients about their aesthetic goals to build a personalized plan that achieves the natural-looking results they desire."

BOTOX® Cosmetic Day, recognized by the National Day Archives as an official holiday on the National Day Registry, is held annually on the third Wednesday of November.

BOTOX® Cosmetic Day is made possible with AllÄ, which connects more than 7 million Members with nearly 30,000 practices. Since its inception, AllÄ has provided consumers with access to exclusive offers and rewards on aesthetic treatments while supporting practices with simplified tools and resources. It remains the most robust loyalty program in aesthetics and the first to allow Members to earn points on more than 50 non-Allergan Aesthetics treatments and brands.

For more information on BOTOX® Cosmetic Day, to purchase gift cards or to enroll in AllÄ, please visit botoxcosmeticday.com.

*Limited-time offer, while supplies last. Terms and Conditions apply.

â See AllÄ app for full Refer a Friend Terms and Conditions. Offer is exclusive to AllÄ Members. Between November 1-30, your friend must register for AllÄ and get treated for you (the Referrer) to qualify for $50 off any qualifying AllÄ product or treatment. Maximum of one referral offer per Member. To receive a $50 offer for your referral, your friend's consent and treatment are required.

â¡In a phase 4 study, 90.5% of patients treated with BOTOX® Cosmetic reported being "Mostly satisfied" or "Very satisfied" with their natural-looking results at Day 30 on the FLSQ follow-up item 4, the study's primary endpoint.

§BOTOX® Cosmetic was the first neurotoxin approved by the U.S. FDA for aesthetic use in 2002.

IIIn the BOTOX® Cosmetic phase 3 clinical trials, full results were seen in 30 days for frown lines, forehead lines, and crow's feet (upper facial lines) in adults.

About Allergan Aesthetics 

At Allergan Aesthetics, an AbbVie company, we develop, manufacture and market a portfolio of leading aesthetics brands and products. Our aesthetics portfolio includes facial injectables, body contouring, plastics, skin care and more. Our goal is to consistently provide our customers with innovation, education, exceptional service and a commitment to excellence, all with a personal touch. For more information, visit allerganaesthetics.com. 

About AbbVie

AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology â and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.

References:

- BOTOX® Cosmetic Prescribing Information, October 2024.

- Allergan Aesthetics. Data on file, Neurotoxin Monthly Tracker Report, August 2026.

- Allergan Aesthetics. Data on file, BOND Study. November 2025.

- Allergan Aesthetics. Data on file, Be BOLD Study. November 2025.

BOTOX® Cosmetic (onabotulinumtoxinA) Important Information

APPROVED USES

BOTOX® Cosmetic is a prescription medicine that is injected into muscles and used to temporarily improve the look of moderate to severe forehead lines, crow's feet lines, frown lines between the eyebrows and vertical bands connecting the jaw and neck (platysma bands) in adults.

IMPORTANT SAFETY INFORMATION

BOTOX® Cosmetic may cause serious side effects that can be life threatening. Get medical help right away if you have any of these problems any time (hours to weeks) after injection of BOTOX® Cosmetic:

- Problems swallowing, speaking or breathing, due to weakening of associated muscles, which can be severe and result in loss of life. You are at the highest risk if these problems are preexisting before injection. Swallowing problems may last for several months.

- Spread of toxin effects. The effect of botulinum toxin may affect areas away from the injection site and cause serious symptoms, including loss of strength and all-over muscle weakness, double vision, blurred vision and drooping eyelids, hoarseness or change or loss of voice, trouble saying words clearly, loss of bladder control, trouble breathing and trouble swallowing.

BOTOX® Cosmetic dosing units are not the same as, or comparable to, any other botulinum toxin product.

There has not been a confirmed serious case of spread of toxin effect when BOTOX® Cosmetic has been used at the recommended dose to treat frown lines, crow's feet lines, forehead lines and/or platysma bands.

BOTOX® Cosmetic may cause loss of strength or general muscle weakness, vision problems or dizziness within hours to weeks of receiving BOTOX® Cosmetic. If this happens, do not drive a car, operate machinery or do other dangerous activities.

Serious and/or immediate allergic reactions have been reported, including itching, rash, red itchy welts, wheezing, asthma symptoms or dizziness or feeling faint. Get medical help right away if you are wheezing or have asthma symptoms, or if you become dizzy or faint.

Do not receive BOTOX® Cosmetic if you are allergic to any of the ingredients in BOTOX® Cosmetic (see Medication Guide for ingredients); had an allergic reaction to any other botulinum toxin product such as Myobloc (rimabotulinumtoxinB), Dysport (abobotulinumtoxinA), Xeomin (incobotulinumtoxinA), Jeuveau (prabotulinumtoxinA-xvfs), Daxxify (daxibotulinumtoxinA-lanm) or Letybo (letibotulinumtoxinA-wlbg); or have a skin infection at the planned injection site. This list may not include all available botulinum toxin products.

Tell your doctor about all your muscle or nerve conditions, such as ALS or Lou Gehrig's disease, myasthenia gravis or Lambert-Eaton syndrome, as you may be at increased risk of serious side effects, including difficulty swallowing and difficulty breathing, from standard doses of BOTOX® Cosmetic.

Tell your doctor about all your medical conditions, including surgery or plans to have surgery on your face, trouble raising your eyebrows, drooping eyelids, any other abnormal facial change, are pregnant or plan to become pregnant (it is not known if BOTOX® Cosmetic can harm your unborn baby) or are breastfeeding or plan to (it is not known if BOTOX® Cosmetic passes into breast milk).

Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements. Using BOTOX® Cosmetic with certain other medicines may cause serious side effects. Do not start any new medicines until you have told your doctor that you have received BOTOX® Cosmetic in the past.

Rocket Rx Launches Rocket Melts: Fast-Dissolving Sublingual ED Treatment Designed to Start Working in as Few as 15 Minutes

A new under-the-tongue format offers a quicker, easier way to take treatment, with less forward-planning

DELRAY BEACH, Fla., Oct. 28, 2026 /PRNewswire/ -- Rocket Rx, a US telehealth brand from HeliosX, today announced the launch of Rocket Melts, a fast-dissolving sublingual treatment for erectile dysfunction (ED) combining sildenafil and tadalafil in a single mint and citrus flavor pill, available by prescription through rocketrx.com.

Rocket Melts are designed to deliver effective results from as few as 15 minutes, at lower doses, with the potential for fewer side effects. Traditional ED pills often mean planning 30-60 minutes ahead. Rocket Melts are designed for when sex doesn't stick to a schedule.

A faster, easier format

Rocket Melts dissolve under the tongue within 3 minutes. There's nothing to swallow and no water needed, so taking treatment is simple and discreet.

Designed for the moment

Rocket Melts are designed so you can stay in the moment (and not in your head).

Clinician-led prescribing

Each prescription is determined by a licensed clinician following an online consultation, based on the individual patient's needs and medical history.

"Many men find that planning intimacy around a pill that takes up to an hour to work can feel inconvenient or disruptive. Rocket Melts work fast, leaving space for spontaneity without the worry."

Dr. Ashley White, Medical Director - North America, HeliosX

"Rocket Melts rethink how ED treatment fits into real life. We've created a format that's faster and more discreet to take, while every prescription stays grounded in the same clinical oversight."

Dr. Karim Vellani, Chief Medical Officer, HeliosX

How it works

Patients complete an online consultation which is reviewed by a US-licensed clinician. If eligible, a prescription is issued and medication is shipped discreetly.

Availability

Rocket Melts are available from October 28, 2026 at rocketrx.com, in packs of 8, 16 and 32 dissolvable mints.

Important information

Rocket Melts are compounded medications. Prescription treatment only. Following an online consultation, one of Rocket Rx's US-licensed clinicians will determine whether treatment is appropriate. Individual results, onset times and side effects may vary. Compounded drugs are permitted to be prescribed under federal law but are not FDA-approved and do not undergo FDA safety, effectiveness, or manufacturing review.

About Rocket Rx

Rocket Rx gives you the freedom to access safe medication on your terms. No more waiting in line â get genuine prescription treatments delivered straight to your door, quickly and discreetly.

About HeliosX

HeliosX exists to create a world where everyone can afford to access high-quality healthcare. We bring together technology, clinicians, pharmacies, operations, and brand to make care feel faster, safer, and more human.

SOURCE Rocket Rx

Share this article